Royal Bank of Canada’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.36M | Buy |
67,864
+62,688
| +1,211% | +$1.26M | ﹤0.01% | 3335 |
|
|
2025
Q1 | $102K | Buy |
+5,176
| New | +$102K | ﹤0.01% | 4849 |
|
|
2024
Q4 | – | Sell |
-3,763
| Closed | -$96K | – | 6434 |
|
|
2024
Q3 | $96K | Buy |
3,763
+380
| +11% | +$9.69K | ﹤0.01% | 4922 |
|
|
2024
Q2 | $79K | Buy |
3,383
+2,254
| +200% | +$52.6K | ﹤0.01% | 5020 |
|
|
2024
Q1 | $20K | Sell |
1,129
-6,862
| -86% | -$122K | ﹤0.01% | 5471 |
|
|
2023
Q4 | $110K | Buy |
7,991
+3,284
| +70% | +$45.2K | ﹤0.01% | 5028 |
|
|
2023
Q3 | $65K | Buy |
4,707
+1,632
| +53% | +$22.5K | ﹤0.01% | 5145 |
|
|
2023
Q2 | $63K | Buy |
3,075
+2,589
| +533% | +$53K | ﹤0.01% | 5208 |
|
|
2023
Q1 | $11K | Buy |
486
+339
| +231% | +$7.67K | ﹤0.01% | 5872 |
|
|
2022
Q4 | $2K | Buy |
147
+125
| +568% | +$1.7K | ﹤0.01% | 6448 |
|
|
2022
Q3 | $0 | Buy |
22
+14
| +175% | – | ﹤0.01% | 7022 |
|
|
2022
Q2 | $0 | Hold |
8
| – | – | ﹤0.01% | 6949 |
|
|
2022
Q1 | $0 | Hold |
8
| – | – | ﹤0.01% | 7274 |
|
|
2021
Q4 | $0 | Hold |
8
| – | – | ﹤0.01% | 7140 |
|
|
2021
Q3 | $0 | Sell |
8
-491
| -98% | – | ﹤0.01% | 7123 |
|
|
2021
Q2 | $16K | Buy |
499
+289
| +138% | +$9.27K | ﹤0.01% | 6165 |
|
|
2021
Q1 | $7K | Buy |
210
+108
| +106% | +$3.6K | ﹤0.01% | 6429 |
|
|
2020
Q4 | $9K | Buy |
102
+99
| +3,300% | +$8.74K | ﹤0.01% | 5861 |
|
|
2020
Q3 | $0 | Buy |
+3
| New | – | ﹤0.01% | 6167 |
|